CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer

The authors evaluated the activity of AMG 910, a CLDN18.2-targeted half-life extended bispecific T cell engager (BiTE) molecule in gastric cancer and pancreatic ductal adenocarcinoma preclinical models, and cocultured Tregs and effector T cells in the presence of CLDN18.2-HLE-BiTE.